Literature DB >> 3653175

Modulation of natural killer cell activity by tamoxifen in stage I post-menopausal breast cancer.

J Berry1, B J Green, D S Matheson.   

Abstract

Tamoxifen, an antiestrogen which competes for the estrogen receptor, modulates natural killer cell activity in vivo. Seventeen post-menopausal stage I breast cancer patients received tamoxifen for 1 month and a statistically significant increase in NK activity was demonstrated (P = 0.0005). There was a small incremental shift in the number of Leu-11b positive cells. These data demonstrate that tamoxifen functions as a biological response modifier.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3653175     DOI： 10.1016/0277-5379(87)90313-0

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN： 0277-5379


  11 in total

1.  Effects of the antiestrogen toremifene on growth of the human mammary carcinoma cell line MCF-7.

Authors:  R Grenman; K M Laine; P J Klemi; S Grenman; D J Hayashida; H Joensuu
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

2.  Relations of plasma ACTH and cortisol levels with the distribution and function of peripheral blood cells in response to a behavioral challenge in breast cancer: an empirical exploration by means of statistical modeling.

Authors:  G van der Pompe; M H Antoni; H J Duievenvoorden; C J Heijnen
Journal:  Int J Behav Med       Date:  1997

3.  Successful management of multi-focal hepatic infantile hemangioendothelioma using TACE/surgery followed by maintenance metronomic therapy.

Authors:  Vishal Sondhi; Purna Arun Kurkure; Tushar Vora; Shripad D Banavali; S Vishwanathan; Seema Medhi; Anirudh Kulkarni; Sajid Quereshi; Brijesh Arora
Journal:  BMJ Case Rep       Date:  2012-03-08

4.  Can tamoxifen prevent breast cancer?

Authors:  A H Paterson; P H Geggie
Journal:  CMAJ       Date:  1993-01-15       Impact factor: 8.262

5.  Natural killer cell activity, phagocytosis, and number of peripheral blood cells in breast cancer patients treated with tamoxifen.

Authors:  J Lukac; Z Kusić; D Kordić; M Koncar; A Bolanca
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

6.  The immunological status of breast cancer patients during treatment with a new antiestrogen, toremifene.

Authors:  R Valavaara; J Tuominen; A Toivanen
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

7.  In vivo modulation of natural killer cell activity by tamoxifen in patients with bilateral primary breast cancer.

Authors:  E Robinson; D Rubin; T Mekori; R Segal; S Pollack
Journal:  Cancer Immunol Immunother       Date:  1993-08       Impact factor: 6.968

Review 8.  Gynaecologic effects of tamoxifen.

Authors:  D Y Kuo; C D Runowicz
Journal:  Med Oncol       Date:  1995-06       Impact factor: 3.064

Review 9.  Endocrine resistance in breast cancer--An overview and update.

Authors:  Robert Clarke; John J Tyson; J Michael Dixon
Journal:  Mol Cell Endocrinol       Date:  2015-10-09       Impact factor: 4.102

10.  Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing.

Authors:  Benjamin Wolfson; Michelle R Padget; Jeffrey Schlom; James W Hodge
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.